Comparative Pharmacology
Head-to-head clinical analysis: METHOCARBAMOL versus RYANODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOCARBAMOL versus RYANODEX.
METHOCARBAMOL vs RYANODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
Ryanodine receptor agonist; stabilizes the ryanodine receptor (RyR1) channel in skeletal muscle, reducing calcium leakage and improving excitation-contraction coupling.
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
Dantrolene sodium: 2.5 mg/kg IV bolus, repeated as needed up to a cumulative dose of 10 mg/kg, then 1 mg/kg IV every 6 hours for 24-48 hours following malignant hyperthermia crisis.
None Documented
None Documented
Clinical Note
moderateMethocarbamol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone propionate."
Clinical Note
moderateMethocarbamol + Venlafaxine
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine."
Clinical Note
moderateMethocarbamol + Nefazodone
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone."
Clinical Note
moderateTerminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation.
Terminal elimination half-life is approximately 1.5-2 hours in healthy adults; prolonged in patients with hepatic impairment.
Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for the majority of elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Methocarbamol + Stiripentol
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol."